In older adults with type 2 diabetes (T2D), the initiation of GLP-1 receptor agonists vs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increased risk for fragility fractures.

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...